1,570 results match your criteria systemic infliximab

Treatment of Generalized Pustular Psoriasis of Pregnancy With Infliximab.

Cutis 2021 Mar;107(3):E2-E5

Dr. Beksac is from the Department of Dermatology, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey. Dr. Adisen is from and Dr. Gurer was from the Department of Dermatology, Gazi University Faculty of Medicine, Ankara, Turkey.

Generalized pustular psoriasis of pregnancy (GPPP) is a rare and severe condition that may impair the health of the mother and fetus. Effective treatment is essential, as treatment options for GPPP are limited due to concerns about unfavorable pregnancy outcomes. We report the case of a 22-year-old woman with GPPP that was unresponsive to systemic corticosteroids. Read More

View Article and Full-Text PDF

Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.

Pediatr Rheumatol Online J 2021 May 1;19(1):62. Epub 2021 May 1.

Department of Pediatrics, Duke University Hospital, Durham, NC, USA.

Background: Inadequate systemic exposure to infliximab (IFX) is associated with treatment failure. This work evaluated factors associated with reduced IFX exposure in children with autoimmune disorders requiring IFX therapy.

Methods: In this single-center cross-sectional prospective study IFX trough concentrations and anti-drug antibodies (ADAs) were measured in serum from children diagnosed with inflammatory bowel disease (IBD) (n = 73), juvenile idiopathic arthritis (JIA) (n = 16), or uveitis (n = 8) receiving maintenance IFX infusions at an outpatient infusion clinic in a tertiary academic pediatric hospital. Read More

View Article and Full-Text PDF

Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.

Pediatr Rheumatol Online J 2021 May 1;19(1):63. Epub 2021 May 1.

Presbyterian Healthcare Services, New Mexico, Albuquerque, USA.

Background: Coccidioides immitis is a dimorphic fungus endemic to the arid climates of the Southwest United States, Mexico and parts of Central and South America. Human infection occurs through inhalation of spores with less than half of exposures progressing to a symptomatic state that primarily consists of pulmonary manifestations. Disseminated coccidioidomycosis is exceedingly rare, occurring in fewer than 1 % of symptomatic infections. Read More

View Article and Full-Text PDF

Unexpected condition in a rare disease: encephalopathy in early-onset sarcoidosis.

Turk J Pediatr 2021 ;63(2):323-328

Department of Pediatric Rheumatology, Erciyes University Faculty of Medicine, Kayseri.

Background: Granulomatous autoinflammatory diseases are monogenic syndromes caused by mutations in the region encoding the nucleotide-binding domain of the nucleotide-binding oligomerization domain-containing 2 gene. Blau syndrome and early-onset sarcoidosis are familial and sporadic forms of the same disease and are very rare. Many organ systems may be involved; however, neurologic involvement is infrequent. Read More

View Article and Full-Text PDF
January 2021

AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings.

Sci Rep 2021 Apr 29;11(1):9289. Epub 2021 Apr 29.

Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.

Studies have shown that the levels of pro-inflammatory adipokines in patients with psoriasis are higher than in general population. The aim of the study was to investigate the influence of 36-month therapy with TNF-α inhibitors (adalimumab, etanercept, infliximab) on the levels of adipokines (resistin, adiponectin, leptin) and lipids (TG, cholesterol, LDL, HDL) in 37 psoriasis patients and 30 healthy controls. The mean serum concentrations of adiponectin in patients from adalimumab, etanercept and infliximab group were similar to control group (p > 0. Read More

View Article and Full-Text PDF

Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes.

Clin Exp Rheumatol 2021 Apr 21. Epub 2021 Apr 21.

Rheumatology and Ophthalmology Unit, Hospital Universitario Marqués de Valdecilla, IDIVAL, Universidad de Cantabria, Santander, Spain.

Objectives: Anti-IL6R tocilizumab (TCZ) therapy has proved to be useful in the treatment of refractory ocular and/or neurological involvement of Behçet's disease (BD). However, TCZ efficacy in other BD manifestations remains unclear. In this study we aimed to assess the efficacy of TCZ in the different clinical phenotypes of BD. Read More

View Article and Full-Text PDF

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev 2021 04 19;4:CD011535. Epub 2021 Apr 19.

Department of Dermatology, Hôpital Henri Mondor, Créteil, France.

Background: Psoriasis is an immune-mediated disease for which some people have a genetic predisposition. The condition manifests in inflammatory effects on either the skin or joints, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Read More

View Article and Full-Text PDF

Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders.

Ann Transl Med 2021 Mar;9(5):430

Department of Dermatology, Brigham and Women's Hospital & Harvard Medical School, Boston, MA, USA.

Inhibition of the proinflammatory cytokine tumor necrosis factor alpha (TNFα) has been utilized as a treatment strategy for a variety of immune-mediated inflammatory disorders (IMID), including rheumatoid arthritis, Crohn's disease and psoriasis. A wide array of biologic therapies targeting the TNFα molecule, including etanercept, infliximab, certolizumab, golimumab and adalimumab, are routinely used in the care of patients with these conditions. In addition to their therapeutic potential, anti-TNFα agents commonly induce the formation of autoantibodies such as anti-nuclear antibodies and anti-double stranded DNA antibodies; however, the vast majority of these are of IgM isotype and of unclear clinical significance, uncommonly leading to drug-induced autoimmune disease. Read More

View Article and Full-Text PDF

Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab.

Case Rep Oncol 2021 Jan-Apr;14(1):386-390. Epub 2021 Mar 10.

Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.

We present the case of a 73-year-old male patient with a history of tobacco use who presented with a central nervous system mass that was confirmed to be a lung adenocarcinoma metastasis. High PD-L1 expression as well as negativity to other targetable drivers led to initiation of pembrolizumab monotherapy and ablative stereotactic radiation therapy on oligo-residual disease, achieving a complete response after 2 years of therapy. Following discontinuation of systemic treatment, the patient developed widespread desquamative plaques. Read More

View Article and Full-Text PDF

Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.

Pediatr Rheumatol Online J 2021 Mar 25;19(1):46. Epub 2021 Mar 25.

Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, Spitalstrasse 33, CH 4031, Basel, Switzerland.

Background: Biologic disease modifying antirheumatic drugs (bDMARDs) and Janus Kinase (JAK) inhibitors are prescribed in adult and paediatric rheumatology. Due to age-dependent changes, disease course, and pharmacokinetic processes paediatric patients with inflammatory rheumatic diseases (PiRD) differ from adult rheumatology patients.

Methods: A systematic literature search for randomized clinical trials (RCTs) in PiRD treated with bDMARDs/JAK inhibitors was conducted on Medline, clinicaltrials. Read More

View Article and Full-Text PDF

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.

Gut 2021 05 22;70(5):865-875. Epub 2021 Mar 22.

Division of Digestive Diseases, Faculty of Medicine, Imperial College London, London, UK.

Objective: Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections. We sought to determine whether infliximab-treated patients with IBD have attenuated serological responses to SARS-CoV-2 infections.

Design: Antibody responses in participants treated with infliximab were compared with a reference cohort treated with vedolizumab, a gut-selective anti-integrin α4β7 monoclonal antibody that is not associated with impaired vaccine responses or increased susceptibility to systemic infections. Read More

View Article and Full-Text PDF

Ulcerative cutaneous sarcoidosis successfully treated with infliximab.

Clin Rheumatol 2021 Mar 16. Epub 2021 Mar 16.

Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, 1611 W Harrison Street, suite 510, Chicago, IL, 60612, USA.

Sarcoidosis is a systemic inflammatory disorder with cutaneous involvement present in 25% of cases. We present a patient with ulcerative sarcoidosis to highlight this unusual presentation of a relatively rare cutaneous condition that was treated successfully using infliximab. The drug is effective in cutaneous sarcoidosis, but relapses can occur after discontinuation. Read More

View Article and Full-Text PDF

Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study.

Mol Clin Oncol 2021 Apr 8;14(4):65. Epub 2021 Feb 8.

Department of Medical Oncology, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Osaka 541-8567, Japan.

The present study investigated outcomes of infliximab (IFX) treatment among 8 Japanese patients with various types of cancer (4 with malignant melanoma, 3 with lung cancer and 1 with renal cancer) who developed severe steroid-resistant immune-related adverse events (irAEs) in association with immune checkpoint inhibitors (ICIs) to determine its efficacy and safety. Information, including patient background, treatment progress, examination data and imaging data, was collected retrospectively from electronic medical records. Adverse reactions were evaluated using the Common Terminology Criteria for Adverse Events version 4. Read More

View Article and Full-Text PDF

Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.

Auto Immun Highlights 2021 Mar 6;12(1). Epub 2021 Mar 6.

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.

Background: Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and infliximab has improved the treatment of ocular manifestations in GPA.

Case Report: We report a case of a 45-year-old Caucasian male suffering with rhinitis, sinubronchitis and exophthalmos. Read More

View Article and Full-Text PDF

Sterile subconjunctival abscess in an HLA-B51-positive patient with ulcerative colitis.

Am J Ophthalmol Case Rep 2021 Jun 9;22:101033. Epub 2021 Feb 9.

Department of Ophthalmology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.

Purpose: To report a rare case of aseptic abscess presenting as a subconjunctival abscess in an HLA-B51-positive patient with ulcerative colitis.

Observations: A 25-year-old, male, Japanese patient with ulcerative colitis presented with an unilateral subconjunctival abscess. Infective endocarditis with endophthalmitis was suspected of being the cause, and systemic antimicrobial therapy was begun. Read More

View Article and Full-Text PDF

Case Report: Systemic Small-Vessel Vasculitis in an Adolescent With Active Ulcerative Colitis.

Front Pediatr 2021 10;9:617312. Epub 2021 Feb 10.

Department of Pediatric Gastroenterology, Hepatology and Nutrition, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

Small-vessel vasculitis (SVV) is a rare immunological disease that affects arterioles, capillaries and venules. It causes purpura, but can also manifest in other organs, including the gastrointestinal tract. SVV and inflammatory bowel disease (IBD) co-occur more frequently than would be expected by chance. Read More

View Article and Full-Text PDF
February 2021

Reperfusion of retinal ischemia in retinal occlusive vasculitis with nicotinic acid and infliximab in Adamantiades-Behçet's disease.

Am J Ophthalmol Case Rep 2021 Mar 5;21:101027. Epub 2021 Feb 5.

Byers Eye Institute, Stanford University, Palo Alto, CA, USA.

To describe a case of ischemic retinal vasculitis in Adamantiades-Behçet disease (ABD) that demonstrated significant resolution of retinal ischemia following treatment with nicotinic acid and infliximab.: A 12-year-old male with a history of recurrent oral ulcers, fevers, and failure to thrive was admitted to the hospital with fever, oral and perirectal mucositis, and poor oral intake one month before presentation to uveitis clinic. He was suspected to have ABD and was treated with three doses of intravenous (IV) methylprednisolone (30 mg/kg/day) which led to improvement in his systemic symptoms. Read More

View Article and Full-Text PDF

Chlorambucil combination therapy in refractory serpiginous choroiditis: A cure?

Am J Ophthalmol Case Rep 2021 Mar 30;21:101014. Epub 2021 Jan 30.

Massachusetts Eye Research and Surgery Institution, Waltham, MA, United States.

Purpose: To find a remedy for serpiginous choroiditis refractory to oral prednisone and chlorambucil treatment.

Observations: Eight eyes of four patients (all female) with advanced macular involvement secondary to serpiginous choroiditis were included in the study. The average age of the patients was 45. Read More

View Article and Full-Text PDF

Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.

J Ocul Pharmacol Ther 2021 May 28;37(4):236-240. Epub 2021 Jan 28.

Uludag University School of Medicine, Pediatric Immunology and Rheumatology, Bursa, Turkey.

Management of uveitis displays a particular challenge in childhood. This study aims to compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in pediatric noninfectious uveitis that were refractory to conventional immunosuppresives. This retrospective single-center study included 33 patients who were treated with anti-tumor necrosis factor (TNF) agents (16 with IFX and 17 with ADA). Read More

View Article and Full-Text PDF

[Systemic Rosai-Dorfman-Destombes disease associated with a myelodysplastic syndrome. Efficacy of hematologic treatment].

Rev Med Interne 2021 Apr 21;42(4):281-284. Epub 2021 Jan 21.

Service de médecine interne, Hôtel-Dieu, Nantes 44000, France.

Introduction: We report an original observation of multifocal refractory Destombes-Rosai-Dorfman disease associated with a myelodysplastic syndrome. The treatment of myelodysplasia allowed a good and prolonged response of both pathologies.

Case Report: A 35-year-old patient was investigated for bilateral exophthalmia, histologically related to Destombes-Rosai-Dorfman disease. Read More

View Article and Full-Text PDF

SARS-CoV-2-associated multisystem inflammatory syndrome in children: clinical manifestations and the role of infliximab treatment.

Eur J Pediatr 2021 May 16;180(5):1581-1591. Epub 2021 Jan 16.

Division of Infectious Diseases, Children's Hospital of Michigan, 3901 Beaubien Blvd, Detroit, MI, 48201, USA.

This study was conducted to assess the clinical spectrum, management, and outcome of SARS-CoV-2-related multisystem inflammatory syndrome in children (MIS-C). We reviewed medical records of children with MIS-C diagnosis seen at the Children's Hospital of Michigan in Detroit between April and June 2020. Thirty-three children were identified including 22 who required critical care (group 1) and 11 with less intense inflammation (group 2). Read More

View Article and Full-Text PDF

Inflammatory Bowel Disease Presenting With Concurrent COVID-19 Multisystem Inflammatory Syndrome.

Pediatrics 2021 Jan 7. Epub 2021 Jan 7.

Division of Gastroenterology, Hepatology and Nutrition and

Coronavirus disease 2019 is associated with a postinfectious multisystem inflammatory syndrome in children (MIS-C). This syndrome is marked by cytokine storm and multiorgan dysfunction, often affecting the gastrointestinal tract, the heart, and the hematopoietic system. We describe the case of a 16-year-old boy with an initial presentation of severe inflammatory bowel disease and concurrent MIS-C. Read More

View Article and Full-Text PDF
January 2021

Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis.

Ther Adv Musculoskelet Dis 2020 16;12:1759720X20969261. Epub 2020 Dec 16.

Service de rhumatologie, Centre National de Référence des Maladies Autoimmunes et Systémiques Rares, Hôpital de Hautepierre, 1 Avenue Molière BP 83049, Strasbourg Cedex, 67098, France.

Background: Pathogenic inflammatory pathways are largely shared between different autoimmune and inflammatory diseases (AIDs). This offers the potential to develop a given targeted therapy in several AIDs.

Methods: We analyzed two clinical trials registries (ClinicalTrials. Read More

View Article and Full-Text PDF
December 2020

[DRESS syndrome induced by sulfasalazine. Report of one case].

Rev Med Chil 2020 Aug;148(8):1213-1218

Clínica Las Condes, Santiago, Chile.

DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) is a severe, rare and potentially lethal idiosyncratic condition associated with the use of some drugs. Given its broad spectrum of presentation, clinical suspicion is essential for management, since it requires the immediate withdrawal of the culprit drug, support measures and the use of corticosteroids as the first line of treatment. We report a 24-year-old woman with a diagnosis of ulcerative colitis with joint involvement despite the use of infliximab, who presented symptoms, signs and laboratory compatible with DRESS syndrome on the third week after indicating sulfasalazine for her baseline disease. Read More

View Article and Full-Text PDF

TNF-α Inhibitors for the Management of Intractable Corneal Melt: Report of Three Cases and Review of the Literature.

Eye Contact Lens 2021 Jan 4;Publish Ahead of Print. Epub 2021 Jan 4.

Department of Ophthalmology (C.A.U., D.Ö., B.A., I.D.), Dokuz Eylul University, Izmir, Turkey; Izmir Biomedicine and Genome Center (C.A.U.), Izmir, Turkey; and Department of Rheumatology (M.B., A.K.), Dokuz Eylul University, Izmir, Turkey.

Objective: To report three consecutive cases with noninfectious corneal melting, whose disease progression could only be halted with tumor necrosis-α (TNF-α) inhibitor infusion, with a review of the relevant literature.

Materials And Methods: Patients with toxic epidermal necrolysis, severe alkaline burn, and Sjögren syndrome had experienced severe corneal melting following penetrating keratoplasty, Boston type 1 keratoprosthesis implantation or spontaneously, respectively. Topical autologous serum eye-drops, medroxyprogesterone, and acetylcysteine formulations; frequent nonpreserved lubrication; systemic tetracyclines and vitamin-C supplements; topical and systemic steroids and steroid-sparing agents; surgical approaches including amniotic membrane transplantation, tectonic graft surgery; and tarsorraphy failed to alter the disease courses. Read More

View Article and Full-Text PDF
January 2021

Monthly Intravitreal Infliximab in Behçet's Disease Active Posterior Uveitis: A Long-Term Safety Study.

Retina 2020 Dec 28;Publish Ahead of Print. Epub 2020 Dec 28.

Department of Ophthalmology Department of Internal Medicine, Kasr El Aini Hospital, Cairo University, El-Manial, Cairo, Egypt.

Purpose: To study the safety of extended monthly intravitreal infliximab injections in patients with active posterior uveitis in Behcet's disease (APUBD).

Methods: This is a prospective, interventional, noncomparative, open-label, pilot study of 9 monthly intravitreal infliximab injections (1mg/0.05ml) for twenty-two eyes of 16 patients with APUBD. Read More

View Article and Full-Text PDF
December 2020

Autoimmune inner ear disease: A systematic review of management.

Laryngoscope Investig Otolaryngol 2020 Dec 28;5(6):1217-1226. Epub 2020 Nov 28.

Department of Otolaryngology-Head and Neck Surgery University of Florida Gainesville Florida USA.

Objectives: The study systematically reviewed the existing literature on the management of autoimmune inner ear disease (AIED).

Study Design: Systematic review.

Methods: We performed a literature search of Embase, NCBI, Cochrane, and Web of Science databases from April 1990 to April 2020. Read More

View Article and Full-Text PDF
December 2020

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations.

J Eur Acad Dermatol Venereol 2020 Nov;34(11):2461-2498

Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. Read More

View Article and Full-Text PDF
November 2020

Dapsone-induced DRESS after infliximab-induced vasculitis: a case of cerebral infarction in the context of multiple drug reactions.

BMJ Case Rep 2020 Dec 17;13(12). Epub 2020 Dec 17.

Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia, USA.

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a life-threatening condition characterised by peripheral eosinophilia, rash and multi-organ failure arising several weeks after exposure to the culprit medication. Although rare, DRESS syndrome triggered by specific agents has been associated with specific genetic polymorphisms more prevalent in different ethnic groups, including an association between dapsone-induced DRESS and Human Leukocyte Antigen (HLA)-B:13*01, a single nucleotide polymorphism more prevalent in those of Asian descent. DRESS and drug-related vasculitis may affect any organ system including the central nervous system (CNS), usually manifesting as encephalitis, meningitis or embolic cerebrovascular accidents related to eosinophilic cardiac disease and thrombosis. Read More

View Article and Full-Text PDF
December 2020